Physician profile
Perry L Bartelt
NPI 1760461529
$1,842.06
in general payments reported to CMS, 2019-2025
22 companies · $227 in 2025
The $227 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $265 · 2020: $185 · 2021: $281 · 2022: $380 · 2023: $231 · 2024: $274 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $731.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $731.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $654.88 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $264.87 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $200.73 | 2019-2023 | Jardiance, Synjardy, Trijardy Xr |
| Astrazeneca Pharmaceuticals LP | $95.76 | 2020-2024 | Airsupra, Farxiga |
| Abbvie INC. | $81.78 | 2021-2025 | |
| Amarin Pharma, INC. | $74.18 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.13 | 2021-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.37 | 2021-2024 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $44.71 | 2019-2021 | |
| Abbott Laboratories | $43.42 | 2025 | Freestyle Libre 3 |
| Boston Scientific Corporation | $32.34 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.92 | 2022 | |
| Janssen Pharmaceuticals, INC | $26.38 | 2021 | |
| Glaxosmithkline, LLC. | $26.32 | 2022-2023 | Trelegy Ellipta |
| Corium, LLC | $26.31 | 2024 | Azstarys |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $18.39 | 2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $15.80 | 2019 | |
| Exact Sciences Corporation | $15.65 | 2023 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $14.36 | 2025 | Contrave |
| Amgen INC. | $13.67 | 2019 | |
| Ironshore Pharmaceuticals INC. | $12.93 | 2023 | Jornay Pm |
| Genentech USA, INC. | $12.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Perry Bartelt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.